LONDON, Sept 7 (Reuters) – Shares of Novartis fell 3.3% on Monday ‌morning after its cholesterol ‌drug failed in a closely watched study, ​casting fresh doubt on the therapeutic approach and raising the stakes for the Swiss drugmaker’s upcoming data ‌for a gene ⁠therapy.

Late on Friday, Novartis said its drug pelacarsen did ⁠not cut heart attack and stroke risk in a large, late-stage ​study of ​patients with ​high Lp(a), an ‌inherited, cholesterol-related risk factor with no approved targeted treatments.

The failure raises the bar for rival Lp(a)-lowering drugs from Amgen and Eli Lilly, ‌both running late-stage trials. ​It also increases ​the pressure ​on data from an ‌experimental muscular dystrophy drug ​del-desiran, which ​Novartis spent $12 billion to acquire last year.

Analysts had modeled peak ​annual sales ‌between $3 billion and $6 billion for ​pelacarsen.

(Reporting by Bhanvi Satija; Editing ​by Joe Bavier)